Drug Profile


Alternative Names: Farydak; LBH-589; LBH-589A

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Georgia Regents University; H. Lee Moffitt Cancer Center and Research Institute; HOVON Foundation; Mayo Clinic; National Cancer Institute (USA); New York University School of Medicine; Novartis; Peter MacCallum Cancer Centre; St. Jude Childrens Research Hospital; Therapeutic Advances in Childhood Leukemia & Lymphoma; Thomas Jefferson University; University of Aarhus; University of Texas M. D. Anderson Cancer Center; University of Wisconsin-Madison
  • Class Antineoplastics; Hydroxamic acids; Indoles; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase II/III Chronic myeloid leukaemia
  • Phase II Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myelomonocytic leukaemia; Colorectal cancer; Graft-versus-host disease; Lymphoma; Myelodysplastic syndromes; Myelofibrosis; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Renal cell carcinoma; Thyroid cancer; Waldenstrom's macroglobulinaemia
  • Phase I/II Breast cancer; HIV-1 infections; Hodgkin's disease
  • Phase I Brain metastases; CNS cancer; Gastrointestinal stromal tumours; Head and neck cancer; Malignant melanoma; Mantle-cell lymphoma; Non-small cell lung cancer; Solid tumours
  • Preclinical Small cell lung cancer
  • No development reported Glioma; Pancreatic cancer
  • Discontinued Cutaneous T cell lymphoma; Prostate cancer

Most Recent Events

  • 24 Jan 2017 Novartis terminates a phase-II trial in Myelodysplastic syndromes (Second-line therapy or greater) in Germany due to lack of efficacy of single agent LBH 589 in the four month open label core phase and due to enrollment difficulties (PO) (NCT01034657)
  • 01 Jan 2017 Novartis terminates a phase I trial in Hodgkin's disease or non-Hodgkin's lymphoma (Second-line therapy or greater) due to lack of funding in USA (PO) (NCT01032148)
  • 21 Dec 2016 Icahn School of Medicine at Mount Sinai in collaboration with Novartis completes a phase II trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (NCT01651039)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top